Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed malignancy

- Metastatic or unresectable disease

- Standard curative or palliative measures do not exist, are no longer effective,
have been completed, or have been refused

- CEA-positive tumor (either by immunohistochemistry or as demonstrated by elevated CEA
> 50 μg/L)

- No primary brain tumor or brain metastases

PATIENT CHARACTERISTICS:

- WHO performance status 0-1

- Life expectancy ≥ 3 months

- Hemoglobin ≥ 10 g/dL

- Platelet count ≥ 100 x 10^9/L

- Neutrophil count ≥ 2.0 x 10^9/L

- Lymphocyte count ≥ 1.0 x 10^9/L

- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT/AST ≤ 5 times ULN

- Alkaline phosphatase ≤ 5 times ULN

- Calculated creatinine clearance OR isotope clearance measurement ≥ 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception 4 weeks prior to, during, and for 6
months after completion of study therapy (male patients must use barrier-method
contraception)

- LVEF ≥ 50% on MUGA scan (for patients receiving cyclophosphamide)

- ECG and exercise ECG (or stress ECHO) normal (may be abnormal but not clinically
significant)

- Urine dipstick normal (may be abnormal but not clinically significant)

- No medical high risk due to nonmalignant systemic disease including active
uncontrolled infection

- No known serologically positive hepatitis B, hepatitis C, HIV, or HTLV

- No history of autoimmune disease

- No inflammatory bowel disease

- No concurrent congestive heart failure or prior history of NYHA class III-IV cardiac
disease

- No concurrent malignancies originating from other primary sites, except for
adequately treated cone-biopsied carcinoma in situ of the cervix uteri or basal cell
or squamous cell carcinoma of the skin

- No other condition that, in the investigator's opinion, would make the patient an
unsuitable candidate for the clinical trial

PRIOR CONCURRENT THERAPY:

- At least 30 days since prior and no concurrent participation in another clinical
trial

- At least 4 weeks since prior and no concurrent radiotherapy (except for palliative
reasons [i.e., control of bone pain])

- At least 4 weeks since prior and no concurrent endocrine therapy, immunotherapy, or
chemotherapy (6 weeks for nitrosoureas and mitomycin C)

- No toxic manifestations of previous treatment, except for alopecia or certain grade 1
toxicities that, in the opinion of the investigator and CRUK (Cancer Research UK),
would exclude the patient (e.g., grade 1 neuropathy or grade 1 fatigue)

- No prior major thoracic and/or abdominal surgery from which the patient has not yet
recovered

- No prior bone marrow transplant or extensive radiotherapy to > 25% of bone marrow

- No concurrent systemic steroids or other immunosuppressive therapy

- No other concurrent anticancer therapy or investigational drugs